Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04069273 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma

Study acronym: SEQUEL
StatusActive, Not Recruiting
PhasePhase 2
Started2020-12-01
View on ClinicalTrials.gov ↗
Cohort 1 \[CLOSED\] Study treatment involves two segments: (1) Induction Immunotherapy segment with pembrolizumab monotherapy every 3 weeks until irRECIST PD and (2) Combination Therapy segment. Nab-paclitaxel may be utilized in place of paclitaxel at investigator's discretion for subjects with paclitaxel reactions. Cohort 2 Patients are randomized to Arm A or B. Treatment in both arms includes pembrolizumab + RAM + paclitaxel.

Amendment history 4 changes detected by DataLookout

2026-09-04
Primary completion pushed: 2026-08-11 → 2027-08-11
2026-09-04
Completion pushed: 2026-12-10 → 2027-12-10
2026-07-29
Enrollment closed, study ongoing
2026-07-29
Primary completion pushed: 2026-06-11 → 2026-08-11
Trial Details
NCT Number NCT04069273
Lead Sponsor Harry H Yoon
Collaborators: Merck Sharp & Dohme LLC, Mayo Clinic
Conditions Gastric Cancer, GastroEsophageal Cancer, Adenocarcinoma
Enrollment 58 participants
Start Date 2020-12-01
Primary Completion 2027-08-11 (estimated)
Study Completion 2027-12-10 (estimated)
Updated on ClinicalTrials.gov 2026-09-03